Claim: In 2026, a trial tested that people maintained on a reduced dose of Tirzepatide kept the weight off just as well as those on higher doses.
Verdict: Incorrect (60% confidence)
Explanation: According to PubMed, the SURMOUNT-MAINTAIN trial in 2026 tested Tirzepatide for weight maintenance and included reduced doses (source 1). Medscape reports that new trial data suggest some patients maintained meaningful weight loss after stepping down from the maximum dose of Tirzepatide (source 4). However, no source explicitly confirms that reduced doses were as effective as higher doses in maintaining weight loss, leaving this specific outcome unverified. Therefore, while the trial and reduced...